csirt@kutim:~/threat-intel/cve/CVE-2024-37166

Katalog CVE

CVSS 8.9 · High EPSS 0,44%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'). Skor CVSS 3.1 8.9 (High) menurut github.com.

Deskripsi (NVD)

ghtml is software that uses tagged templates for template engine functionality. It is possible to introduce user-controlled JavaScript code and trigger a Cross-Site Scripting (XSS) vulnerability in some cases. Version 2.0.0 introduces changes to mitigate this issue. Version 2.0.0 contains updated documentation to clarify that while ghtml escapes characters with special meaning in HTML, it does not provide comprehensive protection against all types of XSS attacks in every scenario. This aligns with the approach taken by other template engines. Developers should be cautious and take additional measures to sanitize user input and prevent potential vulnerabilities. Additionally, the backtick character (`) is now also escaped to prevent the creation of strings in most cases where a malicious actor somehow gains the ability to write JavaScript. This does not provide comprehensive protection either.

Rincian

Terbit di NVD
10 Juni 2024
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 3.1
8.9 (High), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:H/I:H/A:L · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
CWE-80: Improper Neutralization of Script-Related HTML Tags in a Web Page (Basic XSS)
EPSS (30 hari)
0,44% peluang dieksploitasi; lebih tinggi dari 36,1% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.